How does polycythemia vera affect intervertebral disc health and spinal pathology?

Impact of Polycythemia Vera on Spinal Discs

Polycythemia vera does not directly affect intervertebral disc health, but it can cause serious spinal complications through two distinct mechanisms: spinal cord infarction from thrombosis and spinal cord compression from extramedullary hematopoiesis.

Primary Spinal Complications

Thrombotic Spinal Cord Infarction

The most clinically significant spinal complication of PV is acute spinal cord infarction, which occurs due to the disease's prothrombotic state. PV creates hyperviscosity and platelet activation that dramatically increases systemic thrombosis risk 1.

• A documented case showed a 66-year-old woman with PV (platelet count 847,000/μL) who developed acute paraparesis and urinary retention from spinal cord infarction at T12-L1 1
• The same patient had multiple thrombi filling the abdominal aortic lumen, demonstrating the systemic nature of thrombotic risk 1
• This represents a medical emergency requiring immediate recognition and treatment

Extramedullary Hematopoiesis with Cord Compression

The second mechanism is extradural spinal cord compression from extramedullary hematopoiesis (EH), which occurs when hematopoietic tissue develops outside the bone marrow. A case report documented a 68-year-old man with PV who developed gradually progressive paraparesis followed by acute, painless paraplegia from extradural thoracic spinal cord compression secondary to EH 2.

Clinical Implications for Morbidity and Mortality

The thrombotic complications pose the greatest threat to patient outcomes. Among patients with PV:

• 16% experience arterial thrombosis prior to or at diagnosis 3
• 7% have venous thrombotic events, which can involve unusual sites like splanchnic veins 3
• Median survival from diagnosis ranges from 14.1 to 27.6 years across cohorts 3

Prevention Strategy

All patients with PV require aggressive thrombosis prevention regardless of spinal symptoms:

1. Therapeutic phlebotomy to maintain hematocrit <45% 3
2. Low-dose aspirin (unless contraindicated) 3
3. Cytoreductive therapy (hydroxyurea or interferon) for high-risk patients:
   • Age ≥60 years
   • Prior thrombosis history
   • Persistent symptoms 3

Critical Pitfalls

• Do not dismiss acute neurological symptoms (paraparesis, urinary retention, back pain with neurological deficits) in PV patients as musculoskeletal issues—these may represent spinal cord infarction requiring emergency evaluation
• Extreme thrombocytosis (≥1000 × 10⁹/L) paradoxically increases bleeding risk through acquired von Willebrand disease, complicating the clinical picture 3
• Spinal cord compression from EH typically presents more gradually than thrombotic infarction, but both require urgent imaging 2

The intervertebral discs themselves are not pathologically affected by PV, but the spinal cord and surrounding structures face significant risk from the disease's hematologic abnormalities.